INTRODUCTION {#sec1-1}
============

In May 2012, a 69-year-old male patient, with a medical history of bilateral hypoacusia and tinnitus, had a contrast-enhanced magnetic resonance imaging (MRI) diagnosis of left vestibular schwannoma with synchronous meningioma on the left frontal lobe. After 6 months, due to the worsening of symptoms, the patient underwent a partial surgical resection of the acoustic neuroma, whose cellular architecture was classified as "Antoni B" pattern, followed by stereotactic radiosurgery on the remnant (planning target volume \[PTV\], 6.7 cm^3^ covered with a margin dose of 12 Gy).

During that time, the patient, also, had a metachronous prostate cancer (cT2cN0cM0, Gleason score of 4 + 3 and prostate-specific antigen \[PSA\] of 9 ng/mL) treated with a conformal radiotherapy associated to 6 months of hormone therapy with luteinizing hormone/releasing hormone analog.

PROCEDURE {#sec1-2}
=========

In January 2017, during follow-up, PSA increased to 0.27 ng/mL and the patient underwent an 18F-methylcholine positron emission tomography/computed tomography (18F-choline PET/CT). The whole-body scan demonstrated increased tracer uptake at level of the left cerebellopontine angle and of the left frontal lobe \[[Figure 1](#F1){ref-type="fig"}\], corresponding to the known vestibular schwannoma and meningioma (maximum standardized uptake value, respectively, 4.4 and 5.8). A subsequent brain contrast-enhanced MRI showed an increased dimension of the left cerebellopontine schwannoma (25 mm vs. 22 mm) and a dimensional stability of the left frontal meningioma compared with previous MRI dating to 6 months earlier.

![Positron emission tomography/computed tomography showing high grade of 18F-choline uptake (black arrow) in the left cerebellopontine neuroma (a-f) and in the left frontal meningioma (white arrow) (d-f)](WJNM-18-187-g001){#F1}

CONCLUSION {#sec1-3}
==========

It is well known that PET-based molecular imaging, as demonstrated with tracers as 11-C methionine, may contribute to the evaluation, treatment planning, and follow-up of patients with skull base meningiomas and schwannoma.\[[@ref1]\] In a recent review, Calabria *et al*.\[[@ref2]\] underlined the potential role of choline metabolism PET tracers in the detection of benign and malignant brain tumors. Recently, Malamitsi *et al*.\[[@ref3]\] described as an incidental findings on 18F-choline PET/CT of an acoustic schwannoma. To the best of our knowledge, we described the first case of 18F-choline PET\\CT uptake in a local recurrence of a vestibular schwannoma after stereotactic radiotherapy. In the era of "Precision Medicine," it is intriguing the hypothesis that radiolabeled choline, as demonstrated for gliomas,\[[@ref1]\] may be considered also in this setting as a biomarker able to predict an aggressive biology of a brain nonmalignant lesion.\[[@ref4]\]
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